Full-Time
Posted on 1/13/2025
Biotechnology firm creating health and sustainability solutions
Mid, Senior
Cambridge, MA, USA
You match the following Flagship Pioneering's candidate preferences
Employers are more likely to interview you if you match these preferences:
Flagship Pioneering fosters a culture of groundbreaking advancements in biotechnology, emphasizing an ecosystem approach that synergizes human health and sustainability. Their business model not only focuses on creating transformative products but also incubates leading companies like Moderna and Indigo Agriculture, positioning them at the forefront of scientific innovation and industry leadership. This approach offers employees a unique opportunity to be part of a pioneering team that drives real-world impacts across multiple sectors.
Company Size
201-500
Company Stage
N/A
Total Funding
$10.2B
Headquarters
Cambridge, Maryland
Founded
2000
Help us improve and share your feedback! Did you find this helpful?
Professional Development Budget
Flexible Work Hours
First of its Kind Scientific Collaboration Will Engage Top Research Institutes in Cambridge, UK with Flagship PioneeringFocus on Scaling and Advancing Flagship's Breakthrough Science and Technologies through the Cambridge Life Sciences EcosystemLONDON, Jan. 23, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced an agreement with top life science organisations Cambridge University Health Partners (CUHP) and the Milner Therapeutics Institute (MTI) to collaborate to jointly advance breakthrough scientific research and technologies
The following year, Flagship Pioneering formally announced the launch of privately-held Valo, joining with other undisclosed investors to bring the company's total financing to nearly $100 million.
Massachusetts agtech startup Inari Agriculture Inc. said it raised $144 million of new equity at a $2.17 billion valuation, a roughly 32% jump from a prior mark of $1.65 billion set last January.
Flagship Pioneering, a bioplatform company, entered agreements with Ampersand Biomedicines and Montai Therapeutics to identify targeted molecules that could be further developed as treatments for obesity and non-small cell lung cancer (NSCLC).
Ampersand's AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets. Montai's CONECTA™ AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related target. Collaborations will leverage Pfizer's deep expertise in early discovery and development for cardiometabolic and cancer treatments, two priority therapeutic areas for the company
Former Pfizer exec Angela Hwang is joining Flagship Pioneering as a CEO-partner and chief executive of its startup Metaphore Biotechnologies on Jan. 1, the incubator...
Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori BioApriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccinesCAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori
Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.
Flagship Pioneering, the bioplatform innovation company, today announced that Junaid Bajwa, M.D., has joined its London office as Senior Partner and Head of United Kingdom.